Nuvigil (Armodafinil) Patent Expiration, LOE Window & CMS Spending

Nuvigil (Armodafinil) by Nuvo (Ireland) Dac: Off-Patent Genericized (AB Competition), 4 AB generics, $6.6M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNuvo (Ireland) Dac
FDA Application & PathwayN021875 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$6.6M
2024 Medicare Part D Spend$3.5M
2024 Medicaid Spend$3.1M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 18.1% 2-yr change)